1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

SPARC broadens rights R&D funding amid unpredictability

 
• By Anju Ghangurde

Sun Pharma Advanced Research Company (SPARC) has proposed revised plans to deploy the balance of Rs965.87 million ($17.9 million) remaining from a rights issue, including for clinical trials of "equally promising" products such as its lead steroid for allergic rhinitis S0597 and a latanoprost plus timolol ophthalmic combination.

Sun Pharma Advanced Research Company (SPARC) has proposed revised plans to deploy the balance of Rs965.87 million ($17.9 million) remaining from a rights issue, including for clinical trials of "equally promising" products such as its lead steroid for allergic rhinitis S0597 and a latanoprost plus timolol ophthalmic combination.

SPARC, which is the listed spin-off R&D arm of Sun Pharma of India, had earlier earmarked about Rs1.02 billion (to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

PureTech Ponders Way Forward As CEO Exits

 
• By Kevin Grogan

Bharatt Chowrira departs days after firm’s chair stepped down.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

More from Therapeutic Category